T he development and widespread use of drugs that inhibit the actions of vascular endothelial growth factor (veGF) has revolutionized the treatment of common chorioretinal vascular diseases such as neovascular age-related macular degeneration (naMD), diabetic macular edema (DMe), and retinal vein occlusion (rvO).
1-3 aflibercept (eylea; regeneron, tarrytown, NY and Bayer Healthcare, leverkusen, Germany), the most recently approved anti-veGF drug, is comparably effective to other antiveGF agents [ranibizumab (lucentis; Genentech, South San Francisco, ca and roche, Basel, Switzerland) and bevacizumab (avastin; Genentech, South San Francisco, ca and roche, Basel, Switzerland)] in most clinical situations and possibly superior in others.
2,4-7 Despite these recent advances, the search for a more cost-effective alternative continues.
Ziv-aflibercept (Zaltrap; regeneron, tarrytown, NY and Bayer Healthcare, leverkusen, Germany) contains the same therapeutic molecule as eylea and was approved in 2012 for the treatment of metastatic colorectal carcinoma. 8 it has recently been used as an intravitreal treatment of various chorioretinal vascular diseases. Several case series demonstrated that intravitreal zivaflibercept is safe and effective as both short-term and long-term therapy.
9-12 Ziv-aflibercept has been used in several areas of the world because it seems to be as effective as other anti-veGF drugs and is highly cost effective.
13-15 However, its availability remains limited and literature supporting its use remains sparce. the intent of this review article is to summarize existing peer-review data and the authors' personal experience.
Structure
Ziv-aflibercept is a 115 kDa recombinant protein composed of the second extracellular binding domain of veGFr1 and the third extracellular binding domain of veGFr2 fused to the Fc region of a human igG1 molecule. it is identical to intraocular aflibercept, the first veGF-trap drug approved by the United States Food and Drug administration (FDa) for intravitreal injection. aflibercept's strong binding affinity to veGF 165 (k D = 0.45 pM) is 100 times that of both bevacizumab and ranibizumab. 16 Ziv-aflibercept also binds all isoforms of veGF-B and placental growth factor (PlGF), which may explain its efficacy in some clinical conditions. 17 cytotoxicity Ziv-aflibercept's osmolarity (1000 mOsm/kg) is more than 3 times that of aflibercept (300 mOsm/kg), thus making it hyperosmolar with respect to the vitreous. this difference results from purification methods and buffer solutions added during manufacturing.
18 Because intravitreal injections of hyperosmolar solutions (osmolarity > 500 mOsm/kg) irreversibly damage retinal pigment epithelium (rPe) in rabbits and primates, 19 experimental studies have evaluated the safety of intravitreal ziv-aflibercept in humans.
Malik et al, 20 using 2 mg/0.08 ml as a clinical dose of zivaflibercept, reported that 10 times the clinical dosage (10x) adversely affected human rPe cell viability with statiscally significant reduction (P < 0.0001), whereas one half (0.5x), 1 (1x), and 2 times (2x) the usual dose did not lead to significant reduction of viable rPe cells. Significant mitochondrial toxicity denoted by decrease in mitochondrial membrane potential occured when human retinal pigment epithelial cells (arPe 19) were subjected to 10x, 2x, and 1x dose of ziv-aflibercept. at the specified dosage, the final membrane potentials were 10x (49.65 ± 4.22%; P = 0.0002), 2x (64.83 ± 2.7%; P < 0.0001), and 1x dose (73.50 ± 2.93%; P < 0.0001). the osmolarity of culture media at 0.5x, 1x, 2x, and 10x doses of ziv-aflibercept were 324, 330, 342, and 418 mOsm/kg, respectively, with control showing an osmolarity of 328 mOsm/kg, suggesting that only the 10x dose led to a significant difference in osmolarity of culture media. 20 in a preclinical study in rabbits (18 eyes), de Oliveira et al 21 noted no adverse changes when arPe cells were exposed to clinical doses (concentration of 25 mg/ml) of ziv-aflibercept. Optical coherence tomography (Oct) and electroretinogram (erG) were normal at 1 week, with histology and transmission electron microscopy showing no major signs of toxicity.
21 the absence of in vivo damage may be attributed to the minimal increase in vitreous osmolarity after 1.25 mg/0.05 ml ziv-aflibercept injections. the relatively large volume of the adult vitreous (4 ml) dilutes the small volume (0.05 to 0.08 ml) of injected ziv-aflibercept so that intravitreal osmolarity rises from 300 mOsm/kg to approximately 312 mOsm/kg, well below the 500 mOsm/kg threshold required for rPe damage.
18,19

Safety
Several short-and intermediate-term (6 months) human studies that featured intravitreal ziv-aflibercept for various retinal disorders did not find adverse clinical effects or abnormalities on erG or macular microperimetric testing. 9,13,14,22,23 chhablani et al 10 found no clinical or significant erG abnormalities (a and b wave implicit time or amplitude, b/a ratio) in 12 patients with naMD at 1 month after a single injection of intravitreal ziv-aflibercept (1.25 mg/0.05 ml). Mansour et al 12 studied 60 patients (65 eyes) including both treatment-naive and previously treated cases of naMD (32), DMe (25), central rvO (crvO; 6), and pseudophakic central macular edema (cMe; 2) with bevacizumab (160 injections), ranibizumab (29), aflibercept (3), triamcinolone (3), and dexamethasone implant (8). these patients were treated for a mean of 9.2 (range, 6-18) months with at least 6 ziv-aflibercept injections with the standard dose of 1.25 mg/0.05 ml. the authors reported no major ocular or systemic adverse effects except for 1 patient with mild self-limiting iritis. Patients received a mean of 8.4 (range, 8-17) injections according to a pro re nata (PrN) regimen and were evaluated clinically and with imaging, but without erG testing. 12 to the best of our knowledge, endophthalmitis after intravitreal ziv-aflibercept has not yet been reported. this observation stems from the data derived from the available case series involving 250 eyes with a total of approximately 1000 intravitreal ziv-aflibercept injections in different clinical settings and variable follow-up ranging from 1 month to 12 months.
9-12,14,15 we attribute this to compounding experience acquired from the use of aliquoted bevacizumab. Moreover, with a reported incidence of 1 in 4500 intravitreal injections, the sample size of 1000 zivaflibercept injections explains the plausibility of no reports of endophthalmitis to date. 24, 25 the commercially available single-use vials of ziv-aflibercept are available as 100 mg/4 ml or 200 mg/8 ml (ie, concentration of 25 mg/ml). the addition of different kinds of buffer solutions (including polysorbate 20, sodium phosphate, sodium chloride, and sucrose) in varying concentrations accounts for the difference in osmolarity between ziv-aflibercept (1000 mOsm/kg) and aflibercept (300 mOsm/kg).
9 the final intravitreal dose of zivaflibercept is 1.25 mg/0.05 ml, which is 62.5% of the clinical dose of aflibercept (2 mg/0.05 ml).
5-7 the concentration in the commercially available vial is not altered and the only variable parameter is the intravitreal dose of ziv-aflibercept ranging from 1.25 mg/0.05 ml to 2 mg/0.08 ml.
9-12,20 thus, no dilution of the drug is warranted, with different study groups including our group following similar protocols.
we aliquot ziv-aflibercept under a laminar flow hood with strict aseptic techniques. aliquots of 0.1 ml ziv-aflibercept (final intravitreal dose of 1.25 mg/0.05 ml) are drawn into multiple 1-ml syringes after single puncture of the 4-ml single-use bottle. each syringe containing 2.5 mg of ziv-aflibercept in 0.1 ml is stored at 4°c until used, or it is discarded at 2 weeks. a small sample from the vial is directly plated on chocolate agar to look for any inadvertent contamination. andrade et al 14 have reported a similar aliquoting technique wherein a commercially available vial containing 4 ml ziv-aflibercept is repackaged in glass vials in an aspetic filling facility. Mansour et al 9 have used a singlepuncture technique in a sterile hood with freshly aliquoted drug used within hours.
clinical experience in VariouS retinal DiSorDerS neovascular age-related Macular Degeneration
Mansour et al 18 studied a cohort of 30 patients, including 11 treatment-naive and 19 treatment-resistant patients who received a mean 5.2 injections of bevacizumab and ranibizumab on a PrN basis with an injection-free period of 4 months. Patients received monthly ziv-aflibercept injections in a dose of 1.25 mg/0.05 ml for 3 consecutive months. the authors noted improvements in both central macular thickness (cMt) (from a baseline of 332.8 ± 135.1 µm to 208.2 ± 50.9 µm; P < 0.001) and best corrected visual acuity [BCVA; Δ −0.6 logarithm of the minimum angle of resolution (logMar)] at 3 months across both subgroups. treatment-naive cases had a better response, with reduction of cMt from 415.5 ± 144.6 µm to 212.7 ± 51.0 µm (P = 0.008) and improvement in BCVA (Δ −0.7 logMAR) (P = 0.008) at 3 months. 18 aflibercept has been proven to be effective in eyes that respond poorly to either bevacizumab or ranibizumab.
to 90 days after switch to ziv-aflibercept). the mean number of injections during the 12 months after switching to ziv-aflibercept was 5.9 ± 3.2, a reduction of 2.5 injections. this reduced treatment frequency has the potential to reduce both direct and indirect costs.
26 representative cases are shown in Figures 1, 2, and 3. Pigment epithelial detachments (PeDs) have responded favorably to intravitreal ziv-aflibercept. we have reported reduction in height of PeD (from baseline 382 µm to 140 µm, which was maintained at 4-month follow-up) with resolution of submacular hemorrhage in a case of treatment-resistant naMD (after 3 bevacizumab and 5 ranibizumab injections) with a single intravitreal injection of ziv-aflibercept. 27 we have reported reduction in height of PeD in 9 out of 12 eyes with bevacizumab (mean, 5.83 injections) and ranibizumab (mean, 2.3 injections) in resistant naMD. at 12 months (after a mean 6.1 injections of ziv-aflibercept on a PRN basis), the mean PED height was 162.69 ± 183.4 μm compared with the baseline of 198.69 ± 210.4 μm (P = 0.075).
26 these resemble previous reports of PeD reduction with aflibercept in cases of naMD that were poorly responsive to ranibizumab and bevacizumab. conditions including pathological myopia (PM), macular telangiectasia (Mactel), central serous chorioretinopathy (cScr), angioid streaks, choroiditis, Best disease, and choroidal osteoma, or they may be idiopathic. Broadhead and chang 29 have reported good 12-month results in patients with cScr-related cNvM after a single injection of aflibercept. Brue et al 30 reported similar outcomes with single injections of aflibercept for PM-associated cNvM, with resolution of cNvM in half of the patients. aflibercept has been found to be effective in bevacizumab-or ranibizumab-resistant cases of angioid streaks, along with choroidal osteoma-related CNVM.
31,32
we reported variable results after intravitreal ziv-aflibercept injections for non-naMD cNvM. the etiologies including the total number of eyes were pathological myopia (9), idiopathic juxtafoveal retinal telangiectasia or Mactel (4), cScr (3), and idiopathic (1), with 2 cases each of choroidal osteoma, choroiditis, and Best disease. Out of a total of 23 eyes with non n-aMD cNvM, 12 eyes were treatment-naive and 11 eyes had received 2.6 ± 3.5 (mean ± SD) injections of bevacizumab and/or ranibizumab. there was a gap of 2.4 ± 2.4 months between the last anti-veGF injection and the first ziv-aflibercept injection. Mean visual acuity improved from 0.67 ± 0.45 logMar to 0.58 ± 0.43 logMar (P = 0.0507) and mean cMt decreased from 221.6 ± 80.2 μm to 174.5 ± 59.3 μm (P = 0.037). the mean number of injections was 1.35 ± 0.57, with a mean follow-up of 4.1 ± 2.0 months. twelve, 9, and 2 eyes of the total 23 eyes received 1, 2, and 3 intravitreal ziv-aflibercept injections (1.25 mg/0.05 ml), respectively, on a PrN basis. the worst outcomes were seen with choroidal osteoma and eyes treated previously with other antiveGF agents, with 5 eyes losing at least a single line of Bcva in the latter group. Unfortunately, generalizing the results from this small, retrospective study with a short-term follow-up and several underlying etiologies is difficult.
33
Diabetic Macular edema in a small pilot study of 7 treatment-naive patients with type 2 diabetes and DMe, andrade et al 14 evaluated the efficacy and side effect profile of ziv-aflibercept. Patients were administered a total of 6 intravitreal injections (1.25 mg/0.05 ml) repeated every month. there was a reduction of 125.86 ± 65.46 µm in mean cMt from a baseline of 392.0 ± 69.57 µm and mean logMar Bcva improved from 0.78 ± 0.28 to 0.23 ± 0.19 at 6 months (P < 0.001 for each).
14 ashraf et al 34 in treatment-naive DMe patients (14 eyes) reported a significant improvement in Bcva from 0.73 ± 0.39 to 0.38 ± 0.36 (P = 0.013) and cMt reduction from 408.2 ± 77.2 µm to 324.2 ± 70.2 µm (P = 0.001) at 3 months. the patients were injected on a PrN basis (mean number of injections being 2.4 during the 3-month study period) with intravitreal ziv-aflibercept 1.25 mg/0.05 ml. acetonide. the patients were injected with 1.25 mg/0.05 ml zivaflibercept after a washout period of 4-6 weeks on a PRN basis with a mean of 2.03 injections during the course of 3 months. Visual acuity improved (Δ −0.17 logMAR) (P = 0.084) and cMt improved significantly (mean of 513.79 µm before switch to 426.76 µm at 2 months after switch to ziv-aflibercept; P = 0.006) without any adverse effects. the follow-up rate was low at month 3 (10/34 eyes). 36 in another study, ashraf et al 15 compared the outcomes between bevacizumab (1.25 mg/0.05 ml) and ziv-aflibercept (1.25 mg/ 0.05 ml) in 23 and 27 eyes, respectively, with treatment-naive DMe treated on a PrN basis. the visual acuity gain was not significantly different between the 2 groups at 3 months (P = 0.75). However, the anatomic improvement noted in terms of cMt reduction (76.3 µm vs 97.9 µm) was significantly higher in the zivaflibercept group (P < 0.001).
15 these results are in accordance with those from protocol t, where aflibercept reduced cMt better than both bevacizumab and ranibizumab.
central and Branch retinal Vein occlusion
we reported the use of intravitreal ziv-aflibercept in a patient with bilateral recurrent cMe due to crvO who had previously received 12 and 13 bevacizumab injections in the right and left eyes, respectively, and 1 injection of intravitreal triamcinolone acetonide in both eyes with a treatment-free interval of 2 months. a single intravitreal ziv-aflibercept injection (1.25 mg/0.05 ml) reduced CMT (in the right eye from baseline of 834 μm to 193 μm and in the left eye from baseline of 938 μm to 232 μm) and improved visual acuity (from 20/200 to 20/100 in the right eye and 20/200 to 20/159 in the left eye) at 1 month. as no systemic or ocular adverse effects were noted, subsequent studies with a large cohort and longer follow-up were performed.
22
in treatment-naive patients with macular edema due to branch rvO (BrvO), chan et al 37 reported improvements in mean visual acuity (−0.33 ± 0.22 logMAR; P < 0.001) and cMt (271.9 ± 101.8 µm; P < 0.001) after intravitreal injection of ziv-aflibercept (1.25 mg/0.05 ml) on a PrN basis. the authors advocated a PrN regimen considering the self-resolving course of macular edema in a few cases. the patients required a mean of 3.3 ± 1.6 (range, 2-7) injections over a period of 12 months.
37 the results in the study by chan et al 37 
37-39
we reported the efficacy of ziv-aflibercept (standard dose of 1.25 mg/0.05 ml) in eyes with persistent and/or recurrent cMe due to central (5 eyes) and branch rvO (4 eyes) that did not respond favorably to bevacizumab, ranibizumab, dexamethasone implant, or laser photocoagulation. the median number of intravitreal injections received previously was 5, with a treatment-free interval of 11 ± 20 months (mean ± SD). Four months after a mean of 2.3 ± 0.9 ziv-aflibercept injections on a PrN basis, mean CMT decreased from 604 ± 199 μm to 351 ± 205 μm (P = 0.026) and visual acuity improved from 1.0 logMar to 0.71 logMar (P = 0.13). 40 representative cases are shown in Figures  5 and 6 . the recently published results of the ScOre 2 trial compared aflibercept with bevacizumab (noninferiority trial) in cases with central and hemiretinal rvO, including both treatment-naive and nontreatment-naive cases. at 6 months after intravitreal aflibercept and bevacizumab repeated every 4 weeks, visual acuity gain was 18.9 and 18.6 letters, respectively (P = 0.001 for noninferiority).
41
Higher Dose Ziv-aflibercept the most commonly administered dose of ziv-aflibercept is 0.05 ml (1.25 mg), a volume that rarely causes intraocular pressure problems. 9, 10, 18, 34, 36 However, as the approved intravitreal dose of aflibercept (eylea) is 2 mg/0.05 ml, administering an equivalent number of ziv-aflibercept molecules requires an injection volume of 0.08 ml. Short-term (1 month) safety of 2 mg/0.08 ml ziv-aflibercept has been demonstrated in 20 patients with cNvM due to naMD (14), Pcv (3), PM (2), and Mactel (1). at 1 month, no significant erG changes were seen and intraocular pressure remained stable. there was a significant reduction in mean cMt (from 343 ± 177 μm to 210 ± 133 μm; P = 0.01) but visual acuity did not change signficantly (P = 0.72).
11 Unfortunately, the brief follow-up period and inclusion of a small number of eyes with cNvM due to several conditions (naMD, Mactel, Pcv, and PM) prevent generalization of the safety and efficacy results with 2 mg ziv-aflibercept.
econoMic iMpact
Medicare data from the United States in 2010 shows that the yearly cost of treating eye diseases with anti-veGF therapy (bevacizumab and ranibizumab) equals US$2 billion and is estimated to reach US$10 billion within a decade. the reStOre trial, Mitchell et al 43 calculated that ranibizumab monotherapy produces superior improvements in quality adjusted life years (0.17 QalY) compared with either laser monotherapy (0.13 QalY gain) or combination therapy of laser and ranibizumab. Hodgson et al 44 reported that anti-veGF drugs decrease morbidity due to aMD and DMe and significantly improve visual acuity and quality of life.
the wholesale cost of anti-veGF agents (FDa approved) available in United States as per 2015 rates are US$1170 (ranibizumab) and US$1850 (aflibercept). Bevacizumab and ziv-aflibercept are used as off-label drugs and a single vial of 4 ml costs US$660 and US$512, respectively, thus making ziv-aflibercept the cheapest drug among all anti-veGF agents. considering that 1 vial of bevacizumab or ziv-aflibercept is further aliquoted and repackaged, the per injection cost is estimated at US$30-60.
12,45
ross et al 45 analyzed the cost effectiveness of aflibercept, ranibizumab, and bevacizumab based on post hoc analysis from the Diabetic retinopathy clinical research Network comparative effectiveness trial for DMe. the authors concluded that to reach the acceptable US$100,000 cost-effectiveness threshold per disability adjusted life year, the prices of aflibercept and ranibizumab would need a reduction of 69% and 80%, respectively, as compared with bevacizumab for a 10-year period. therefore, at present, prices of aflibercept and ranibizumab are not cost effective compared with bevacizumab in the United States. the situation, however, is not same in all countries. For instance in australia, ranibizumab is covered under the pharmaceutical benefits scheme and is highly subsidized, costing the government aUD$1430 per injection, whereas the patient needs to pay a sum of AUD$36-37.70 per injection. Similarly, aflibercept costs aUD$37.70 per injection and is subsidized only in cases with naMD but not DMe or rvO. On the other hand, nonsubsidized bevacizumab costs anywhere from AUD$80-159 per injection. 46, 47 this cost imbalance may lead to changes in practice patterns, with ranibizumab and aflibercept being preferred over bevacizumab and ziv-aflibercept in the countries such as australia.
However, cost-effectiveness threshholds in countries with high gross domestic product and good medical insurance support do not apply to middle-and low-income countries. as the cost of repeated ranibizumab and aflibercept injections in lower-income countries prohibits sustained therapy, the search for effective and less expensive alternatives continues. when viewed from an economic perspective, increased use of bevacizumab and ziv-aflibercept, instead of the more expensive ranibizumab and aflibercept, makes sense as an affordable solution.
table 1 compares market prices and per injection costs of 4 anti-veGF drugs (these costs are country specific and in this comparison applicable to the United States). Single injections of compounded bevacizumab and ziv-aflibercept cost approximately US$30, whereas single-use vials of ranibizumab and aflibercept cost US$1170 and US$1850, respectively, in the United States. 9, 12 when one considers that most patients need multiple injections to effectively treat their disease, the cost effectiveness of ziv-aflibercept will probably make it an attractive option. Simply by switching from ranibizumab and aflibercept to ziv-aflibercept, the cost of drugs may be reduced by over 95% (table 1) . to properly confirm these extrapolations, larger prospective trials with ziv-aflibercept need to be performed. concluSionS in this era of emerging treatment options for various chorioretinal vascular conditions, ziv-aflibercept may become a valuable addition. the initial concerns regarding its safety and rPe toxicity have been refuted by a series of publications that showed no retinal damage. Both the standard dose (1.25 mg/0.05 ml) and higher dose (2 mg/0.08 ml) of ziv-aflibercept have been shown to produce good anatomic outcomes. the decreased cost of zivaflibercept affords an additional advantage over approved therapies, especially in low-income areas.
However, most of the published literature is in the form of case series (total of approximately 250 eyes) with the largest study of the standard dose (1.25 mg/0.05 ml) involving 65 eyes with a limited follow-up ranging from 1 month to 12 months. the higher 2-mg dose has not been studied extensively (2 case series: 1 preclinical involving rPe cells in culture and 1 clinical study including a total of 21 eyes) with a short follow-up of 1 month. Moreover, these studies have been undertaken by a few investigators in select countries. therefore, direct translation of these results into clinical practice may be difficult at present, in view of the lack of large randomized clinical trials.
at present, the use of intravitreal injections of ziv-aflibercept is off label and along with its limited availability, issues with compounding multiuse vials and lack of long-term data with both standard and higher dose ziv-aflibercept need to be addressed. Positive results from large, multicenter, double-blinded, randomized trials could pave the way for increasing use by physicians across the globe. 
